ASH 2019 | Preliminary promise for venetoclax and 3+7 in untreated AML

Daniel DeAngelo

The results of a phase 1 trial (NCT03709758) of escalating doses of venetoclax with daunorubicin/cytarabine (7+3) induction and high dose cytarabine consolidation in untreated adults acute myeloid leukemia (AML) were presented at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Here Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the preliminary results, which show promise.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter